Equinox Group specializes in predicting the commercial performance of drug programs in all stages of research and development, quantifying the potential for: Patient Share Pricing Market Access Revenue We have evaluated thousands of drug profiles across hundreds of indications in oncology, immunology, rare diseases, cardio-metabolic disorders, infectious diseases, neurology, respiratory, urology, ophthalmology, and endocrine disorders. We also have tailored methods to solve the unique analytical challenges that arise in oncology and rare diseases. Our analytical methods have helped clients around the world solve problems at all stages of R&D.

14 Nov 2019